PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc. an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug Administration (FDA) ...

AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe AJOVY® is the first and only subcutaneous anti-CGRP treatment with both ...

AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe MONTRÉAL, April 8, 2021 /CNW/ - Teva Canada, a subsidiary of Teva ...

Teva Canada launches new Autoinjector for Ajovy to prevent migraine in adults AJOVY now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled ...

The Food and Drug Administration has approved Teva’s Ajovy for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY ® ...

TORONTO, Feb. 4, 2026 /CNW/ - Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for Pr AJOVY® (fremanezumab solution for subcutaneous injection) ...

The 3-month, randomized, placebo-controlled SPACE study enrolled 237 children and adolescents aged 6-17 years with episodic migraine. Participants were randomized to receive monthly subcutaneous ...

MONTRÉAL--(BUSINESS WIRE)--Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary coverage for AJOVY ® (fremanezumab) by Ontario, ...